Experience with phenylethylbiguanide (DBI) tablets and timed-disintegration capsules (DBI-TD) administered as an adjunct to insulin or sulfonylurea drugs in previously treated diabetic patients.
D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D003692:Delayed-Action Preparations; D003920:Diabetes Mellitus / Q000188:drug therapy*; D004357:Drug Synergism; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010629:Phenformin / Q000627:therapeutic use*
D003692:Delayed-Action Preparations; D007004:Hypoglycemic Agents; D007328:Insulin; D010629:Phenformin